Misonix BoneScalpel™ Subject Of New Clinical Paper

              Misonix BoneScalpel™ Subject Of New Clinical Paper

PR Newswire

FARMINGDALE, N.Y., Jan. 29, 2013

FARMINGDALE, N.Y., Jan. 29, 2013 /PRNewswire/ --Misonix, Inc. (NasdaqGM:
MSON), an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery,
skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, was cited in a clinical
paper accepted for publication by "The Laryngoscope," a prestigious,
peer-reviewed journal circulated to leading ear, nose, throat and
reconstructive surgeons, entitled "Piezoelectric BoneScalpel Osteotomies in
Osteocutaneous Free Flaps," authored by Wick, et al, from the Department of
Otolaryngology-Head and Neck Surgery, University Hospitals Ear, Nose, and
Throat Institute; University Hospitals Case Medical Center, Cleveland,
Ohio.Free flaps, in this instance, refer to harvested bone and soft tissue
from donor sites used in reconstructive surgery of the head and neck.

Among the conclusions of the study, it was noted that the Misonix® BoneScalpel
Ultrasonic Bone Cutter offers a safe and efficient method to create precise
cuts during the harvest of bone to be used for reconstructive surgery of the
head and neck, generally required as a result of cancer surgery. Primary
advantages of the device include better tactile control, precise osteotomies
(cuts through bone), a minimal learning curve for the surgeons, and theoretic
protection of vital soft tissue such as vascular structures.

The Misonix® BoneScalpel, which was used to perform the study, is a novel
ultrasonic osteotome (bone cutting device) used for safe, tissue-selective
bone dissection that encourages non-fragmented bone removal and refined
osteotomies while sparing elastic soft tissue structures. Most users report
that the surgical field is relatively bloodless and clean. Loss of viable
bone is minimal and controllable. The BoneScalpel has been used extensively
for bone removal in the cervical, thoracic and lumbar spine, including
deformity surgery. 

"We are proud to be cited by a prestigious peer-reviewed journal for yet
another positive clinical experience with the Misonix BoneScalpel when used in
advanced head and neck surgery," said Michael A. McManus, Jr., President and
Chief Executive Officer of Misonix. "It is our privilege to provide
state-of-the-art head and neck surgery technology to prestigious institutions
such as Cleveland's University Hospitals."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at

Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

                   Investor Relations Contacts
Misonix Contact:   Lytham Partners, LLC
Richard Zaremba    Robert Blum, Joe Dorame, Joe Diaz
631-694-9555       602-889-9700
invest@misonix.com mson@lythampartners.com

SOURCE Misonix, Inc.

Website: http://www.misonix.com
Press spacebar to pause and continue. Press esc to stop.